GeoVax LabsNASDAQ: GOVX

ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will participate in a panel discussion on innovative therapies for solid tumors at the 3rd Annual ROTH Healthcare Opportunities Conference taking place on October 9, 2024 in New York, NY. Senior GeoVax management will also host one-on-one meetings with registered attendees.

ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, will present at two upcoming investor events:

GeoVax Labs NASDAQ: GOVX is currently a micro-cap biotech stock that multiple Wall Street analysts see massive potential appreciation in. Working on a treatment for a disease that the World Health Organization (WHO) just declared a “public health emergency," investors should be informed about the company.

GeoVax Labs Inc.'s stock GOVX, +1.27% tumbled 20% in premarket trade Tuesday, after the clinical-stage biotech said it's entered an agreement with an institutional investor for the purchase and sale of 1.7 million shares priced at $5 each in a registered direct offering. The stock closed Monday up 1.7% at $7.15, after a rollercoaster session that saw it soar more than 40% at its peak, on excitement about its work to develop an mpox vaccine.

GeoVax Labs Inc.'s stock soared 54% early Monday to lead a fresh rally among companies developing treatments for mpox, after rival Siga Technologies Inc. said a trial of its antiviral failed to meet its main goal.

Company to Discuss Recent Mpox Developments as Well as Milestones Related to the BARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine

GeoVax Labs, Inc. (NASDAQ:GOVX ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Max Gadicke - Investor Relations David Dodd - Chairman & Chief Executive Officer Mark Reynolds - Chief Financial Officer Kelly McKee - Chief Medical Officer Conference Call Participants Robert LeBoyer - Noble Capital Markets Jason Kolbert - EF Hutton Jeff Kraws - Crystal Research Operator Good afternoon and welcome everyone to the GeoVax Second Quarter 2024 Corporate Update Call. My name is Alex and I will facilitate today's call.

Biotechnology specialist GeoVax (NASDAQ: GOVX ) — which focuses on developing immunotherapies and vaccines against cancers and infectious diseases — just announced a partnership with global clinical research organization Allucent. The main purpose behind the agreement is to conduct a Phase 2b clinical trial of GeoVax's next-generation Covid-19 vaccine.

GeoVax Labs, Inc. (NASDAQ:GOVX) will be hosting its Q1 2024 Earnings Conference Call on May 14, 2024 at 4:30 PM ET. Company representatives Max Gadicke, David Dodd, Mark Reynolds, Kelly McKee, and John Sharkey will be present. The call will be moderated by Mark.